Author ORCID Identifier
https://orcid.org/0000-0002-1501-3731
https://orcid.org/0000-0001-6771-4364
Document Type
Article
Publication Date
2018
College/Unit
School of Medicine
Department/Program/Center
Pathology, Anatomy and Laboratory Medicine
Abstract
Background. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated significant effects on low-density lipoprotein (LDL) cholesterol and nonhigh density lipoprotein (HDL) cholesterol. To date, there have been limited reports on the effect of PCSK9 inhibitors on remnant cholesterol. Objectives. Assess the effect of PCSK9 inhibitors on nonfasting remnant cholesterol in a real world population. Identify whether pretreatment triglyceride levels are associated with PCSK9 inhibition success as indicated by changes in remnant cholesterol levels. Methods. Patients in our adult lipid clinic (n = 109) receiving PCSK9 inhibition for atherosclerotic cardiovascular disease or familial hypercholesterolemia who had available pre- and post- PCSK9 inhibition standard nonfasting lipid data were, retrospectively, selected for data analysis. Remnant cholesterol was the difference between non-HDL and LDL cholesterol. LDL cholesterol was measured directly and calculated from Friedewald and Martin/Hopkins methods. Data were analyzed using repeated measures ANOVA and multivariable linear regression for differential effects on remnant and LDL cholesterol based upon pretreatment nonfasting triglyceride levels. Results. Remnant cholesterol as well as total, LDL, non-HDL cholesterol, and triglycerides decreased significantly (P
Digital Commons Citation
Morise, Anthony P.; Tennant, Jennifer; Holmes, Sari D.; and Tacker, Danyel H., "The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population" (2018). Faculty & Staff Scholarship. 2029.
https://researchrepository.wvu.edu/faculty_publications/2029
Source Citation
Morise, A. P., Tennant, J., Holmes, S. D., & Tacker, D. H. (2018). The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population. Journal of Lipids, 2018, 1–8. https://doi.org/10.1155/2018/9194736
Comments
Copyright © 2018 Anthony P. Morise et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.